Advertisement

Neuroblastoma pp 193-211 | Cite as

Treatment of Relapsed and Refractory Neuroblastoma

  • Katherine K. Matthay
  • Brian H. Kushner
Part of the Pediatric Oncology book series (PEDIATRICO)

Keywords

Clin Oncol Neuroblastoma Cell Line Arsenic Trioxide Buthionine Sulfoximine Pediatric Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adjei AA, Charron M, Rowinsky EK et al. (1998) Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 4:683–691PubMedGoogle Scholar
  2. Akao Y, Nakagawa Y, Akiyama K (1999) Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 455:59–62CrossRefPubMedGoogle Scholar
  3. Alvarado CS, Kretschmar C, Joshi VV et al. (1997) Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG phase II study. J Pediatr Hematol Oncol 19:62–67CrossRefPubMedGoogle Scholar
  4. Anderson CP, Tsai JM, Chan WW et al. (1997) Buthionine sulfoximine (BSO) is cytotoxic and enhances the activity of melphalan for human neuroblastoma cell lines. Eur J Cancer 33:2016–2019CrossRefPubMedGoogle Scholar
  5. Anderson CP, Seeger RC, Matthay KK, Neglia JP, Bailey HH, Reynolds CP (1998) Pilot study of buthionine sulfoximine (BSO) and melphalan (L-PAM) in children with recurrent neuroblastoma. Proc Am Soc Clin Oncol 17:531aGoogle Scholar
  6. Anderson CP, Tsai JM, Meek WE et al. (1999) Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 246:183–192CrossRefPubMedGoogle Scholar
  7. Aquino VM, Weitman SD, Winick NJ et al. (2004) Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J Clin Oncol 22:1413–1419CrossRefPubMedGoogle Scholar
  8. Ara T, Fukuzawa M, Kusafuka T et al. (1998) Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg 33:1272–1278CrossRefPubMedGoogle Scholar
  9. Bacon CM, McVicar DW, Ortaldo JR, Rees RC, O'Shea JJ, Johnston JA (1995) Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 181:399–404CrossRefPubMedGoogle Scholar
  10. Bailey HH, Ripple G, Tutsch KD et al. (1997) Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 89:1789–1796PubMedGoogle Scholar
  11. Bauer M, Reaman GH, Hank JA et al. (1995) A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 75:2959–2965PubMedGoogle Scholar
  12. Bausero MA, Panoskaltsis-Mortari A, Blazar BR, Katsanis E (1996) Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-gamma. J Immunother Emphasis Tumor Immunol 19:113–124PubMedGoogle Scholar
  13. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ (2004) Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96:46–55PubMedGoogle Scholar
  14. Berg SL, Blaney SM, Adamson PC et al. (1998) Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol 16:181–186PubMedGoogle Scholar
  15. Berg SL, Blaney SM, Sullivan J, Bernstein M, Dubowy R, Harris MB (2000) Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 22:506–509CrossRefPubMedGoogle Scholar
  16. Bjornland K, Bratland A, Rugnes E et al. (2001) Expression of matrix metalloproteinases and the metastasis-associated gene S100A4 in human neuroblastoma and primitive neuroectodermal tumor cells. J Pediatr Surg 36:1040–1044CrossRefPubMedGoogle Scholar
  17. Blanc E, Goldschneider D, Ferrandis E, Barrois M, Le Roux G, Leonce S, Douc-Rasy S, Benard J, Raguenez G (2003) MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol 163:321–331PubMedGoogle Scholar
  18. Blaney SM, Needle MN, Gillespie A et al. (1998) Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res 4:357–360PubMedGoogle Scholar
  19. Bleiberg H (1998) Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77(Suppl 4):1–3Google Scholar
  20. Bowman L, Grossmann M, Rill D et al. (1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92:1941–1949PubMedGoogle Scholar
  21. Bowman LC, Grossmann M, Rill D et al. (1998) Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 9:1303–1311PubMedGoogle Scholar
  22. Brodeur GM, Pritchard J, Berthold F et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment (see comments). J Clin Oncol 11:1466–1477PubMedGoogle Scholar
  23. Brown JM (1998) Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. Br J Cancer 77(Suppl 4):12–14PubMedGoogle Scholar
  24. Burchill SA, Lewis IJ, Abrams KR et al. (2001) Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19:1795–1801PubMedGoogle Scholar
  25. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK (1993) Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 11:623–629PubMedGoogle Scholar
  26. Canete A, Navarro S, Bermudez J, Pellin A, Castel V, Llombart-Bosch A (2000) Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol 18:27–34PubMedGoogle Scholar
  27. Carre M, Carles G, Andre N et al. (2002) Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. Biochem Pharmacol 63:1831–1842CrossRefPubMedGoogle Scholar
  28. Castleberry RP, Cantor AB, Green AA et al. (1994) Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study (see comments). J Clin Oncol 12:1616–1620PubMedGoogle Scholar
  29. Chantrain CF, Shimada H, Jodele S et al. (2004) Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 64:1675–1686PubMedGoogle Scholar
  30. Chen X, Doffek K, Sugg SL, Shilyansky J (2003) Neuroblastoma cells inhibit the immunostimulatory function of dendritic cells. J Pediatr Surg 38:901–905CrossRefPubMedGoogle Scholar
  31. Cheung IY, Lo Piccolo MS, Kushner BH, Kramer K, Cheung NK (2003) Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 21:1087–1093CrossRefPubMedGoogle Scholar
  32. Cheung NK, Modak S (2002) Oral (1->3),(1->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217–1223PubMedGoogle Scholar
  33. Cheung NK, Lazarus H, Miraldi FD et al. (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma (see comments). J Clin Oncol 5:1430–1440PubMedGoogle Scholar
  34. Cheung NK, Munn D, Kushner BH, Usmani N, Yeh SD (1989) Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies. Int J Rad Appl Instrum [B] 16:111–120Google Scholar
  35. Chien CH, Hsieh KH (1990) Interleukin-2 immunotherapy in children. Pediatrics 86:937–943PubMedGoogle Scholar
  36. Cole SP (1990) Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother Pharmacol 26:250–256PubMedGoogle Scholar
  37. Cosetti M, Wexler LH, Calleja E et al. (2002) Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 24:101–105CrossRefPubMedGoogle Scholar
  38. Cox GW, Melillo G, Chattopadhyay U, Mullet D, Fertel RH, Varesio L (1992) Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumoricidal activity. J Immunol 149:3290–3296PubMedGoogle Scholar
  39. Davidoff AM, Kimbrough SA, Ng CY, Shochat SJ, Vanin EF (1999) Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12. J Pediatr Surg 34:902–907CrossRefPubMedGoogle Scholar
  40. Davidson A, Gowing R, Lowis S et al. (1997) Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group UKCCSG. Eur J Cancer 33:1816–1822CrossRefPubMedGoogle Scholar
  41. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK (1992) IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol 148:3125–3132PubMedGoogle Scholar
  42. Dole M, Nunez G, Merchant AK et al. (1994) Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54:3253–3259PubMedGoogle Scholar
  43. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP (1995) Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55:2576–2582PubMedGoogle Scholar
  44. Donfrancesco A, Jenkner A, Castellano A et al. (2004) Ifosfamide/ carboplatin/etoposide (ICE) as front-line, topotecan/ cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr Suppl 93:6–11Google Scholar
  45. Dorie MJ, Brown JM (1993) Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633–4636PubMedGoogle Scholar
  46. Dowlati A, Hoppel CL, Ingalls ST et al. (2001) Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J Clin Oncol 19:2309–2318PubMedGoogle Scholar
  47. DuBois SG, Kalika Y, Lukens JN et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival (see comments). J Pediatr Hematol Oncol 21:181–189CrossRefPubMedGoogle Scholar
  48. Eggert A, Grotzer MA, Zuzak TJ et al. (2001) Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61:1314–1319PubMedGoogle Scholar
  49. Erdreich-Epstein A, Shimada H, Groshen S et al. (2000) Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60:712–721PubMedGoogle Scholar
  50. Eskens FA, Dumez H, Hoekstra R et al.(2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917–926CrossRefPubMedGoogle Scholar
  51. Ettinger LJ, Gaynon PS, Krailo MD et al. (1994) A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer 73:1297–1301PubMedGoogle Scholar
  52. Evans AE, Kisselbach KD, Yamashiro DJ et al. (1999) Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 5:3594–3602PubMedGoogle Scholar
  53. Favrot MC, Michon J, Floret D et al. (1990) Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation. Pediatr Hematol Oncol 7:275–284PubMedGoogle Scholar
  54. Fernandez MC, Krailo MD, Gerbing RR, Matthay KK (2000) A phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma. Cancer 88:2838–2844CrossRefPubMedGoogle Scholar
  55. Fine HA, Figg WD, Jaeckle K et al. (2000) Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708–715PubMedGoogle Scholar
  56. Fine HA, Wen PY, Maher EA et al. (2003) Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21:2299–2304CrossRefPubMedGoogle Scholar
  57. Foa R, Guarini A, Gansbacher B (1992) IL2 treatment for cancer: from biology to gene therapy. Br J Cancer 66:992–998PubMedGoogle Scholar
  58. Frantz CN, London WB, Diller L, Seeger R, Sawyer K (2004) Recurrent neuroblastoma: Randomized treatment with topotecan+cyclophosphamide (T+C) vs. topotecan alone (T). A POG/CCG Intergroup Study. ASCO, abstract no. 8512Google Scholar
  59. Frappaz D, Michon J, Hartmann O et al. (1992) Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 10:1592–1601PubMedGoogle Scholar
  60. Frappaz D, Bouffet E, Perel Y et al. (1998) Phase II study of cisplatinum and carboplatinum CACIS combination in advanced stage neuroblastomas. Med Pediatr Oncol 30:9–14CrossRefPubMedGoogle Scholar
  61. Frost JD, Hank JA, Reaman GH et al. (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80:317–333CrossRefPubMedGoogle Scholar
  62. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM (2001) Sensitization for death receptor-or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20:5865–5877CrossRefPubMedGoogle Scholar
  63. Furman WL, Stewart CF, Poquette CA et al. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815–1824PubMedGoogle Scholar
  64. Furman WL, Crews KR, Daw NC et al. (2003) Cefixime enables further dose-escalation of oral irinotecan in pediatric patients with refractory solid tumors. Proc Am Soc Clin Oncol 22:799Google Scholar
  65. Furumai R, Matsuyama A, Kobashi N et al. (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62:4916–4921PubMedGoogle Scholar
  66. Garaventa A, Gambini C, Villavecchia G et al. (2003) Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 97:1332–1338CrossRefPubMedGoogle Scholar
  67. Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641–661PubMedGoogle Scholar
  68. George DJ, Dionne CA, Jani J et al. (1999) Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 59:2395–2401PubMedGoogle Scholar
  69. Goorin AM, Harris MB, Inoue S et al. (1995) Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. J Pediatr Hematol Oncol 17:265–269PubMedGoogle Scholar
  70. Grem JL, Politi PM, Berg SL et al. (1996) Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochem Pharmacol 51:1649–1659CrossRefPubMedGoogle Scholar
  71. Grupp SA, Stern JW, Bunin N et al. (2000) Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 18:2567–2575PubMedGoogle Scholar
  72. Haas-Kogan DA et al. (2002) Impact of radiotherapy for high risk neuroblastoma: a Children's Cancer Group study. J Clin Oncol 56:28–39Google Scholar
  73. Handgretinger R, Anderson K, Lang P et al. (1995) A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 31A:261–267CrossRefPubMedGoogle Scholar
  74. Hank JA, Surfus J, Gan J et al. (1994) Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 15:29–37PubMedGoogle Scholar
  75. Higashi N, Nishimura Y, Higuchi M, Osawa T (1991) Human monocytes in a long-term culture with interleukin-2 show high tumoricidal activity against various tumor cells. J Immunother 10:247–255PubMedGoogle Scholar
  76. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T (2004) Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 20:33–38CrossRefPubMedGoogle Scholar
  77. Hladik F, Tratkiewicz JA, Tilg H et al. (1994) Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction. J Immunol 153:1449–1454PubMedGoogle Scholar
  78. Ho R, Eggert A, Hishiki T et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62:6462–6466PubMedGoogle Scholar
  79. Houghton PJ, Stewart CF, Cheshire PJ et al. (2000) Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 6:4110–4118PubMedGoogle Scholar
  80. Houghton PJ, Adamson PC, Blaney S et al. (2002) Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 8:3646–3657PubMedGoogle Scholar
  81. Ikeda H et al. (1992) Sites of relapse in patients with neuroblastoma following bone marrow transplantation in relation to preparatory “debulking” treatments. J Pediatr Surg 27:1438–1441CrossRefPubMedGoogle Scholar
  82. Jackson RC, Sebolt JS, Shillis JL, Leopold WR (1990) The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest 8:39–47PubMedGoogle Scholar
  83. Kaicker S, McCrudden KW, Beck L et al. (2003) Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. Int J Oncol 23:1651–1655PubMedGoogle Scholar
  84. Karlsson J, Ora I, Porn-Ares I, Pahlman S (2004) Arsenic trioxide-induced death of neuroblastoma cells involves activation of bax and does not require p53. Clin Cancer Res 10:3179–3188CrossRefPubMedGoogle Scholar
  85. Kellie SJ, de Kraker J, Lilleyman JS, Bowman A, Pritchard J (1988) Ifosfamide in previously untreated disseminated neuroblastoma. Results of study 3A of the European Neuroblastoma Study Group. Eur J Cancer Clin Oncol 24:903–908CrossRefPubMedGoogle Scholar
  86. Kerbel RS, Viloria-Petit A, Klement G, Rak J (2000) 'Accidental’ anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36:1248–1257CrossRefPubMedGoogle Scholar
  87. Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP (2000a) p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 35:563–568CrossRefPubMedGoogle Scholar
  88. Keshelava N, Groshen S, Reynolds CP (2000b) Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother Pharmacol 45:1–8PubMedGoogle Scholar
  89. Keshelava N, Zuo JJ, Chen P et al. (2001) Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61:6185–6193PubMedGoogle Scholar
  90. Keshelava N, Tsao-Wei D, Reynolds CP (2003) Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin Cancer Res 9:3492–3502PubMedGoogle Scholar
  91. Klingebiel T, Bader P, Bares R et al. (1998) Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 34:1398–1402CrossRefPubMedGoogle Scholar
  92. Klingebiel T, Berthold F, Treuner J et al. (1991) Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial. Med Pediatr Oncol 19:84–88PubMedGoogle Scholar
  93. Komuro H, Li P, Tsuchida Y et al. (1994) Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med Pediatr Oncol 23:487–492PubMedGoogle Scholar
  94. Kramer K, Kushner B, Heller G, Cheung NK (2001) Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center experience and a literature review. Cancer 91:1510–1519CrossRefPubMedGoogle Scholar
  95. Kramer K, Kushner BH, Cheung NK (2003) Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol 25:601–605CrossRefPubMedGoogle Scholar
  96. Kreissman SG, Rackoff W, Lee M, Breitfeld PP (1997) High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol 19:309–312CrossRefPubMedGoogle Scholar
  97. Kretschmar CS, Kletzel K, Murray K, Smith EI, Marcus R, Castleberry R (1995) Phase II therapy with taxol and topotecan in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma (NB). A POG study. Med Pediatr Oncol 24:243Google Scholar
  98. Kung FH, Pratt CB, Vega RA et al. (1993) Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 71:1898–1903PubMedGoogle Scholar
  99. Kuo MH, Allis CD (1998) Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20:615–626CrossRefPubMedGoogle Scholar
  100. Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F (2001) Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 28:551–556CrossRefPubMedGoogle Scholar
  101. Kushner BH, Kramer K, Cheung NK (2002) Chronic neuroblastoma. Cancer 95:1366–1375CrossRefPubMedGoogle Scholar
  102. Kushner BH, Kramer K, Cheung NK (1999) Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 17:3221–3225PubMedGoogle Scholar
  103. Ladenstein R, Lasset C, Hartmann O et al. (1993) Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol 11:2230–2341Google Scholar
  104. Ladenstein R, Philip T, Lasset C et al. (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953–965PubMedGoogle Scholar
  105. Langevin AM, Weitman SD, Kuhn JG et al. (2003) Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 25:526–533CrossRefPubMedGoogle Scholar
  106. Langler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F (2002) Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood: a phase-II-study. Klin Padiatr 214:153–156CrossRefPubMedGoogle Scholar
  107. Lashford LS, Lewis IJ, Fielding SL et al. (1992) Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10:1889–1896PubMedGoogle Scholar
  108. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA (1997) Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89:1586–1594CrossRefPubMedGoogle Scholar
  109. Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA (1999) Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 96:8591–8596CrossRefPubMedGoogle Scholar
  110. LoRusso P, Wozniak AJ, Polin L et al. (1990) Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res 50:4900–4905PubMedGoogle Scholar
  111. LoRusso P, Foster BJ, Poplin E et al. (1995) Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). Clin Cancer Res 1:1487–1493PubMedGoogle Scholar
  112. Manohar CF, Bray JA, Salwen HR, Madafiglio J, Cheng A, Flemming C, Marshall GM, Norris MD, Haber M, Cohn SL (2004) MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene 23:753–762CrossRefPubMedGoogle Scholar
  113. Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T (2004) Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 259:269–288PubMedGoogle Scholar
  114. Marminon C, Pierre A, Pfeiffer B et al. (2003) Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety. J Med Chem 46:609–622CrossRefPubMedGoogle Scholar
  115. Mastrangelo S, Tornesello A, Diociaiuti L et al. (2001) Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 84:460–464CrossRefPubMedGoogle Scholar
  116. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC (1993) Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol 11:2226–2233PubMedGoogle Scholar
  117. Matthay KK, DeSantes K, Hasegawa B et al. (1998) Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16:229–236PubMedGoogle Scholar
  118. Matthay KK, Villablanca JG, Seeger RC et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165–1173CrossRefPubMedGoogle Scholar
  119. Matthay KK, Edeline V, Lumbroso J et al. (2003a) Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486–2491CrossRefPubMedGoogle Scholar
  120. Matthay KK, Brisse H, Couanet D et al. (2003b) Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer 98:155–165CrossRefPubMedGoogle Scholar
  121. Meitar D, Crawford SE, Rademaker AW, Cohn SL (1996) Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14:405–414PubMedGoogle Scholar
  122. Middlemas DS, Stewart CF, Kirstein MN et al. (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6:998–1007PubMedGoogle Scholar
  123. Moss TJ, Cairo M, Santana VM, Weinthal J, Hurvitz C, Bostrom B (1994) Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 83:3085–3089PubMedGoogle Scholar
  124. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14:759–767PubMedGoogle Scholar
  125. Nasr S, McKolanis J, Pais R et al. (1989) A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A Pediatric Oncology Group Study. Cancer 64:783–788PubMedGoogle Scholar
  126. Negrier S, Michon J, Floret D et al. (1991) Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma (published erratum appears in J Clin Oncol 1992, 6:1026). J Clin Oncol 9:1363–1370PubMedGoogle Scholar
  127. Ng A, Taylor GM, Eden OB (2000) Secondary leukemia in a child with neuroblastoma while on oral etoposide:What is the cause? Pediatr Hematol Oncol 17:273–279CrossRefPubMedGoogle Scholar
  128. Nishimura Y, Higashi N, Tsuji T, Higuchi M, Osawa T (1992) Activation of human monocytes by interleukin-2 and various cytokines. J Immunother 12:90–97PubMedGoogle Scholar
  129. Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C (1998) Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315–318CrossRefPubMedGoogle Scholar
  130. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M (1996) Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334:231–238CrossRefPubMedGoogle Scholar
  131. O'Dwyer PJ, Hamilton TC, Young RC et al. (1992) Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst 84:264–267PubMedGoogle Scholar
  132. Olgun N, Kansoy S, Aksoylar S et al. (2003) Experience of the Izmir Pediatric Oncology Group on Neuroblastoma: IPOG-NBL-92 Protocol. Pediatr Hematol Oncol 20:211–218PubMedGoogle Scholar
  133. Ora I, Bondesson L, Jonsson C et al. (2000) Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro. Biochem Biophys Res Commun 277:179–185CrossRefPubMedGoogle Scholar
  134. Ozkaynak MF, Seeger RC, Krailo M, Sondel P, Matthay K, Reaman G (1998) Phase I study of chimeric human/murine anti-GD2 monoclonal antibody (ch14.18) with GM-CSF in children with neuroblastoma immediately post hematopoietic stem cell transplantation (HSCT): a Children's Cancer Group study. Proc Am Soc Clin Oncol 17:532aGoogle Scholar
  135. Pais RC, Abdel-Mageed A, Ghim TT et al. (1992) Phase I study of recombinant human interleukin-2 for pediatric malignancies: feasibility of outpatient therapy. A Pediatric Oncology Group Study. J Immunother 12:138–146PubMedGoogle Scholar
  136. Pardo N, Marti F, Fraga G et al. (1996) High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study. Med Pediatr Oncol 27:534–539CrossRefPubMedGoogle Scholar
  137. Park JR, Slattery J, Gooley T et al. (2000) Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol 35:719–723CrossRefPubMedGoogle Scholar
  138. Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA (2003) Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101:649–654CrossRefPubMedGoogle Scholar
  139. Pession A, Prete A, Locatelli F et al. (1998) Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 78:528–533PubMedGoogle Scholar
  140. Pinkerton CR, Zucker JM, Hartmann O et al. (1990) Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group. Br J Cancer 62:319–323PubMedGoogle Scholar
  141. Pourquier P, Waltman JL, Urasaki Y et al. (2001) Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine. Cancer Res 61:53–58PubMedGoogle Scholar
  142. Pratt CB (1992) Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States. Semin Oncol 19:43–49Google Scholar
  143. Pratt CB, Stewart C, Santana VM et al. (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12:539–543PubMedGoogle Scholar
  144. Prudhomme M (2000) Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents. Curr Med Chem 7:1189–1212PubMedGoogle Scholar
  145. Ramnath N, Creaven PJ (2004) Matrix metalloproteinase inhibitors. Curr Oncol Rep 6:96–102PubMedGoogle Scholar
  146. Ribeiro RC, Rill D, Roberson PK et al. (1993) Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer 72:623–628PubMedGoogle Scholar
  147. Riccardi A, Ferlini C, Meco D, Mastrangelo R, Scambia G, Riccardi R (1999) Antitumour activity of oxaliplatin in neuroblastoma cell lines. Eur J Cancer 35:86–90CrossRefPubMedGoogle Scholar
  148. Rill DR, Santana VM, Roberts WM et al. (1994) Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380–383PubMedGoogle Scholar
  149. Roper M, Smith MA, Sondel PM et al. (1992) A phase I study of interleukin-2 in children with cancer. Am J Pediatr Hematol Oncol 14:305–311PubMedGoogle Scholar
  150. Rowinsky EK, Verweij J (1997) Review of phase I clinical studies with topotecan. Semin Oncol 24:S20-3–S20-10Google Scholar
  151. Rowinsky EK, Noe DA, Grochow LB et al. (1995) Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 13:1975–1984PubMedGoogle Scholar
  152. Saleh MN, Khazaeli MB, Wheeler RH et al. (1992) Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 3:19–24PubMedGoogle Scholar
  153. Saylors RL III, Stewart CF, Zamboni WC et al. (1998) Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 16:945–952PubMedGoogle Scholar
  154. Schiavetti A, Varrasso G, Maurizi P, Castello MA (2001) Two secondary leukemias among 15 children given oral etoposide. Med Pediatr Oncol 37:148–149CrossRefPubMedGoogle Scholar
  155. Sebolt JS, Scavone SV, Pinter CD, Hamelehle KL, Hoff DD von, Jackson RC (1987) Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 47:4299–4304PubMedGoogle Scholar
  156. Sebolt J, Havlick M, Hamelehle K, Nelson J, Leopold W, Jackson R (1989) Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24:219–224CrossRefPubMedGoogle Scholar
  157. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK (2000) Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 18:4067–4076PubMedGoogle Scholar
  158. Shitara T, Shimada A, Tsuchida Y, Suzuki N, Toki F, Kuroiwa M (2003) Successful clinical response to irinotecan in relapsed neuroblastoma. Med Pediatr Oncol 40:126–128CrossRefPubMedGoogle Scholar
  159. Shulkin BL, Shapiro B (1998) Current concepts on the diagnostic use of MIBG in children. J Nucl Med 39:679–688PubMedGoogle Scholar
  160. Sigal RK, Lieberman MD, Reynolds JV, Shou J, Ziegler MM, Daly JM (1991) Low-dose interferon gamma renders neuroblastoma more susceptible to interleukin-2 immunotherapy. J Pediatr Surg 26:389–396CrossRefPubMedGoogle Scholar
  161. Smith BD, Levis M, Beran M et al. (2004) Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Blood 63:5559–5563Google Scholar
  162. Smith MA, Parkinson DR, Cheson BD, Friedman MA (1992) Retinoids in cancer therapy. J Clin Oncol 10:839–864PubMedGoogle Scholar
  163. Stokes AH, Lewis DY, Lash LH et al. (2000) Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis. Brain Res 858:1–8CrossRefPubMedGoogle Scholar
  164. Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA (1998) Matrix metalloproteinases-2 and-9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 58:2209–2216PubMedGoogle Scholar
  165. Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC (1993) Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas (see comments). J Natl Cancer Inst 85:377–384PubMedGoogle Scholar
  166. Takasuna K, Hagiwara T, Hirohashi M et al. (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752–3757PubMedGoogle Scholar
  167. Takita J, Ishii M, Tsutsumi S et al. (2004) Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 40:120–132CrossRefPubMedGoogle Scholar
  168. Teitz T, Wei T, Valentine MB et al. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN (see comments). Nat Med 6:529–535CrossRefPubMedGoogle Scholar
  169. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54:4313–4320PubMedGoogle Scholar
  170. Thompson J, Zamboni WC, Cheshire PJ et al. (1997) Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs 8:313–322PubMedGoogle Scholar
  171. Thompson J, George EO, Poquette CA et al. (1999) Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5:3617–3631PubMedGoogle Scholar
  172. Toren A, Nagler A, Rozenfeld-Granot G et al. (2000) Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma. Transplantation 70:1100–1104CrossRefPubMedGoogle Scholar
  173. Troncone L, Rufini V, Luzi S, Mastrangelo R, Riccardi R (1995) The treatment of neuroblastoma with [131I]MIBG at diagnosis. Q J Nucl Med 39:65–68PubMedGoogle Scholar
  174. Truitt RL, Piaskowski V, Kirchner P, McOlash L, Camitta BM, Casper JT (1992) Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. J Immunother 11:274–285PubMedGoogle Scholar
  175. Tubergen DG, Stewart CF, Pratt CB et al. (1996) Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 18:352–361CrossRefPubMedGoogle Scholar
  176. Tucker GC (2003) Alpha v integrin inhibitors and cancer therapy. Curr Opin Invest Drugs 4:722–731Google Scholar
  177. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J (2001) Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res 61:8–13PubMedGoogle Scholar
  178. Tweddle DA, Pearson AD, Haber M et al. (2003) The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197:93–98CrossRefPubMedGoogle Scholar
  179. Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL (1995) Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol Immunother 41:29–36CrossRefPubMedGoogle Scholar
  180. Valteau-Couanet D, Rubie H, Meresse V, Farace F, Brandely M, Hartmann O (1995) Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma. Bone Marrow Transplant 16:515–520PubMedGoogle Scholar
  181. Vassal G, Terrier-Lacombe MJ, Bissery MC et al. (1996) Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74:537–545PubMedGoogle Scholar
  182. Verstovsek S, Eppolito C, Ujhazy P, Maccubbin DL, Ehrke MJ, Mihich E (1995) Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol 23:519–528PubMedGoogle Scholar
  183. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschella G, Dominici C (2003) c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer 106:147–152CrossRefPubMedGoogle Scholar
  184. Voute PA, Hoefnagel CA, de Kraker J, Valdes Olmos R, Bakker DJ, van de Kleij AJ (1991) Results of treatment with 131Imetaiodobenzylguanidine 131 I-MIBG in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res 366:439–445PubMedGoogle Scholar
  185. Wang ZY (2001) Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 48(Suppl 1):S72–S76CrossRefPubMedGoogle Scholar
  186. Watts RG (1992) Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma. Cancer 69:3012–3014PubMedGoogle Scholar
  187. Watts RG, Mroczek-Musulman E (1996) Pulmonary interstitial disease mimicking idiopathic pneumonia syndrome as the initial site of relapse of neuroblastoma following autologous bone-marrow transplantation: a case report. Am J Hematol 53:137–140CrossRefPubMedGoogle Scholar
  188. Weiss B, Vora A, Huberty J, Hawkins RA, Matthay KK (2003) Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 25:543–547CrossRefPubMedGoogle Scholar
  189. Weitman S, Moore R, Barrera H, Cheung NK, Izbicka E, Hoff DD von (1998) In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors. J Pediatr Hematol Oncol 20:136–139CrossRefPubMedGoogle Scholar
  190. Weitman S, Barrera H, Moore R et al. (2000) MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol 22:306–314CrossRefPubMedGoogle Scholar
  191. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38–43PubMedGoogle Scholar
  192. Wigginton JM, Park JW, Gruys ME et al. (2001a) Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166:1156–1168PubMedGoogle Scholar
  193. Wigginton JM, Gruys E, Geiselhart L et al. (2001b) IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 108:51–62CrossRefPubMedGoogle Scholar
  194. Wolden SL, Gollamudi SV, Kushner BH, LaQuaglia M, Kramer K, Rosen N, Abramson S, Cheung NV et al. (2000) Local control with multimodality therapy for Stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys 46:969–974CrossRefPubMedGoogle Scholar
  195. Yanagida T, Kato T, Igarashi O, Inoue T, Nariuchi H (1994) Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. J Immunol 152:4919–4928PubMedGoogle Scholar
  196. Yanik GA, Levine JE, Matthay KK et al. (2002) Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142–2149CrossRefPubMedGoogle Scholar
  197. Yao K, Godwin AK, Ozols RF, Hamilton TC, O'Dwyer PJ (1993) Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 53:3662–3666PubMedGoogle Scholar
  198. Yoshida H, Tanabe M, Miyauchi M et al. (1999) Induced immunity by expression of interleukin-2 or GM-CSF gene in murine neuroblastoma cells can generate antitumor response to established tumors. Cancer Gene Ther 6:395–401CrossRefPubMedGoogle Scholar
  199. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S (2001) Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48Suppl 1:S20–S26CrossRefPubMedGoogle Scholar
  200. Yu AL, Batova A, Alvarado C, Rao VJ, Castleberry RP (1997) Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG Phase II study. Proc Am Soc Clin Oncol 16:513aGoogle Scholar
  201. Yung WK, Prados MD, Yaya-Tur R et al. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  202. Zamboni WC, Bowman LC, Tan M et al. (1999) Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 43:454–460CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Katherine K. Matthay
  • Brian H. Kushner

There are no affiliations available

Personalised recommendations